Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS
- Conditions
- EBV-Positive Diffuse Large B-Cell Lymphoma, NosBrentuximab Vedotin
- Interventions
- Drug: BV+R-CHP
- First Posted Date
- 2025-04-13
- Last Posted Date
- 2025-04-13
- Target Recruit Count
- 25
- Registration Number
- NCT06925555
- Locations
- 🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
Impact of BMI on CDK4/6 Inhibitors Efficacy and Safety in Advanced Breast Cancer
- Conditions
- Advanced Breast Cancer
- Interventions
- Drug: Impact of BMI on CDK4/6 Inhibitors Efficacy and Safety
- First Posted Date
- 2025-04-13
- Last Posted Date
- 2025-04-13
- Target Recruit Count
- 500
- Registration Number
- NCT06926088
- Locations
- 🇨🇳
Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China
Prospective Study on the Safety and Efficacy of Robot-Assisted Laparoscopic Partial Nephrectomy With Renal Artery Off-Clamp in the Treatment of cT1 Renal Tumors
- Conditions
- RCC, Renal Cell CancerPartial Nephrectomy
- First Posted Date
- 2025-04-03
- Last Posted Date
- 2025-04-03
- Target Recruit Count
- 60
- Registration Number
- NCT06908902
- Locations
- 🇨🇳
The first affiliated hospital of Nanjing Medical University, Nanjing, Jiangsu, China
A Trial on the Treatment of Bronchial Asthma With Budesonide Formoterol Combined With Immune Modulators (Staphylococcus and Neisseria Tablets)
- Conditions
- Bronchial Asthma
- Interventions
- Drug: Budesonide FormoterolDrug: PlaceboDrug: Immune Modulators (Staphylococcus and Neisseria Tablets)
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-06-05
- Target Recruit Count
- 198
- Registration Number
- NCT06895460
- Locations
- 🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, Nanjing, Jiangsu, China
Robotic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant Therapy
- Conditions
- Gastric Cancers
- Interventions
- Drug: Pre-operative chemotherapyProcedure: Robotic radical gastrectomy after neoadjuvant therapy
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-07-01
- Target Recruit Count
- 40
- Registration Number
- NCT06895447
- Locations
- 🇨🇳
First Affiliated Hospital of Nanjing Medical Unviersity, Nanjing, Jiangsu, China
🇨🇳First Affiliated Hospital of Nanjing Medical Unviersity, Nanjing, Jiangsu, China
Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected Pancreatic Cancer With High Risk of Recurrence/Metastasis
- Conditions
- Pancreatic CancerMaintenance TherapyPostoperative Adjuvant Therapy
- Interventions
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-04-03
- Target Recruit Count
- 464
- Registration Number
- NCT06779318
- Locations
- 🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes
- Conditions
- ChidamideR-CHOP ChemotherapyDLBCL - Diffuse Large B Cell LymphomaDouble-expressor Lymphoma (DEL)
- Interventions
- Drug: Chidamide plus R-CHOP
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-03-24
- Target Recruit Count
- 148
- Registration Number
- NCT06891157
- Locations
- 🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study
- Conditions
- Rectal Cancer
- Interventions
- First Posted Date
- 2025-03-19
- Last Posted Date
- 2025-03-19
- Target Recruit Count
- 130
- Registration Number
- NCT06884670
Neoadjuvant Therapy for Locally Advanced Rectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- Drug: Anlotinib hydrochloride,Penpulimab
- First Posted Date
- 2025-03-03
- Last Posted Date
- 2025-03-03
- Target Recruit Count
- 48
- Registration Number
- NCT06853769
- Locations
- 🇨🇳
Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China
Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma
- Conditions
- Thymic CarcinomaThymoma
- First Posted Date
- 2025-02-21
- Last Posted Date
- 2025-02-21
- Target Recruit Count
- 20
- Registration Number
- NCT06838910
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China